Gulf study reveals Real-World use of palbociclib for advanced breast cancer

NCT ID NCT04916509

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed study looked at medical records of 258 adults in Saudi Arabia, UAE, and other Gulf countries who received palbociclib (a targeted cancer pill) combined with hormone therapy for advanced HR+/HER2- breast cancer. Researchers aimed to describe patient characteristics, treatment patterns, and outcomes like how long the cancer was controlled. Since this is a retrospective study, it does not test a new treatment but provides real-world insights into how palbociclib is used in this region.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Palbociclib (a targeted cancer drug) combined with either an aromatase inhibitor or fulvestrant

What this could lead to

If successful, this study could help doctors in the Gulf region better understand how palbociclib is used in real-world practice and what outcomes patients experience.

What could go wrong

This is a retrospective study that only looks back at existing data, so it cannot prove cause and effect. Results may not apply to other regions or newer treatment approaches.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dubai Hospital

    Dubai, United Arab Emirates

  • Hamad Medical Corporation

    Doha, Qatar

  • King Abdulaziz Medical City National Guard Hospital

    Jeddah, 22384, Saudi Arabia

  • King Abdulaziz Medical City National Guard Hospital Riyahd

    Riyadh, 11426, Saudi Arabia

  • King Saud University Medical City Riyadh PO BOX 7805

    Riyadh, 11472, Saudi Arabia

  • Mediclinic City Hospital

    Dubai, United Arab Emirates

  • Tawam

    Al Ain City, United Arab Emirates